Answers are grounded in this paper and cite their sources.
Retrospective observational study finds moderate response and survival with R-GemOx in relapsed or refractory large B-cell lymphoma, indicating greater clinical benefit in second-line therapy.
Introduction: Data for the use of rituximab, gemcitabine, and oxaliplatin (R-GemOx) for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the United States are limited. This retrospective observational study characterizes R-GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron Health electronic health record-derived database comprising patient-level data primarily from US community oncology practices. Methods: Patients diagnosed with LBCL who initiated treatment with R-GemOx in the second or later line of therapy between 2011 and 2023, were included. Patient characteristics, treatment patterns, and efficacy outcomes were assessed. Results: Of 281 patients, most (66.2%) were treated at community centers. Overall response rate was 45.4% (95% confidence interval [CI]: 38.1-52.9); complete response (CR) rate was 22.2% (95% CI: 16.4-28.8). Median progression-free and overall survival (OS) were 2.8 months (95% CI: 2.6-3.7) and 12.7 months (95% CI: 10.6-17.1), respectively. In patients who received R-GemOx in the second line, the CR rate was higher and the median OS was longer versus those who received it in later lines (CR rate, 26.3% vs. 17.4%; median OS, 19.6 vs. 10.0 months, respectively). Conclusion: : The authors have confirmed clinical trial registration is not needed for this submission.
No takes yet. Share an insight, caveat, or question.
Budde et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: